Alvimopan Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 12 mg
Reference Brands: Entereg (USA)
Category:
Gastrointestinal Drugs
Alvimopan is available in Capsules
and strengths such as 12 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Alvimopan is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Alvimopan can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Alvimopan, marketed under the trade name Entereg, is a peripherally acting μ-opioid receptor antagonist used to treat postoperative ileus. Unlike centrally acting opioid antagonists, alvimopan has limited ability to cross the blood–brain barrier, allowing it to block μ-opioid receptors in the gastrointestinal tract without reversing the analgesic effects of opioids in the central nervous system. This selective action helps patients recover bowel function more quickly after surgery while still managing pain effectively with opioid medications.
Alvimopan is primarily prescribed for hospitalized patients following bowel resection surgery. It is administered orally in a controlled hospital setting, typically starting prior to surgery and continuing for a limited number of doses postoperatively. By stimulating gastrointestinal motility and reducing the duration of postoperative ileus, alvimopan can shorten hospital stays and improve patient comfort and recovery outcomes. Its use is restricted to FDA-approved indications due to potential cardiovascular risks with long-term administration. When used appropriately under medical supervision, alvimopan is an effective agent for managing postoperative gastrointestinal complications without compromising pain control.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing